Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
Benzinga.com1mon
Vertex 10% Owner Sold $7.80M In Company Stock
Tracking the Wednesday's morning session, Vertex shares are trading at $50.62 ... A higher-than-average P/E ratio of 261.74 suggests caution, as the stock may be overvalued in the eyes of investors.
Zacks.com on MSN2mon
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $460, reflecting a -1.06% shift from the previouse trading day's closing. The stock trailed the S&P 500 ...